What is the prevalence of fulminant hepatitis in acute hepatitis A (HAV), hepatitis B (HBV), hepatitis D (HDV) co‑infection, and hepatitis E (HEV)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 26, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prevalence of Fulminant Hepatitis by Viral Etiology

The risk of fulminant hepatitis varies dramatically by viral type: hepatitis E in pregnant women carries the highest mortality at approximately 25%, followed by hepatitis A in patients with chronic liver disease (up to 40% mortality), while hepatitis B and D show lower but significant rates of fulminant progression.

Hepatitis A (HAV)

General Population

  • Case fatality rates range from 0.01% to 2% in the overall population, with fulminant hepatitis occurring in only 0.14–0.35% of hospitalized cases 1, 2
  • Spontaneous recovery occurs in 30–60% of fulminant HAV cases, with survivors regaining full liver function 1

High-Risk Populations

  • Patients older than 50 years have substantially higher rates of fulminant disease 1
  • Patients with chronic liver disease experience markedly elevated mortality: HAV superinfection in chronic hepatitis C patients resulted in fulminant hepatic failure in 7 of 17 patients (41%), with 6 deaths (35% mortality) in one prospective study 3
  • Chronic hepatitis B patients with cirrhosis show high case fatality rates during HAV superinfection, though most without cirrhosis have uncomplicated courses 4, 3
  • Alcoholic cirrhosis patients demonstrate elevated mortality with HAV superinfection 4

Hepatitis E (HEV)

Pregnant Women

  • The mortality rate in pregnant women is approximately 25%, representing the highest fulminant hepatitis risk among all viral hepatitides 1
  • Deaths result from fulminant hepatic failure and obstetric complications including eclampsia and hemorrhage, with associated high perinatal infant mortality 1

Patients with Chronic Liver Disease

  • Mortality in patients with underlying chronic liver disease approaches 70% at 12 months in some studies from India 1
  • Mortality rates vary widely (0–67%) across different studies of HEV superinfection in chronic liver disease patients 1

General Population

  • HEV genotypes 1 and 2 typically cause brief, self-limiting hepatitis in young adults with low mortality in the absence of pregnancy or chronic liver disease 1

Hepatitis B (HBV)

Acute HBV Alone

  • Acute HBV infection alone has relatively low rates of fulminant hepatitis compared to HAV in high-risk groups 1

HBV/HCV Coinfection

  • Acute coinfection with HBV and HCV may increase the risk of severe hepatitis and fulminant hepatic failure 1

HBV/HDV Coinfection

  • Coinfection with HBV and HDV results in more severe acute hepatitis with higher mortality than HBV alone, but rarely results in chronic infection 1, 5

HBV/HIV Coinfection

  • HIV coinfection increases rates of liver-related mortality but does not specifically increase fulminant hepatitis rates 1

Hepatitis D (HDV)

Coinfection Pattern

  • Simultaneous HBV/HDV coinfection causes more severe acute hepatitis with higher mortality rates than HBV alone 1, 5
  • Chronic infection develops in only approximately 2–5% of coinfection cases 5

Superinfection Pattern

  • HDV superinfection in HBV carriers manifests as severe "acute" hepatitis and results in chronic infection in >90% of cases 1, 5
  • Higher proportions develop cirrhosis, hepatic decompensation, and hepatocellular carcinoma compared to HBV monoinfection 1

Key Clinical Considerations

Age-Related Risk

  • Fulminant hepatitis A is more frequent in individuals older than 40 years, with age >50 years being a poor prognostic indicator 1, 6

Underlying Liver Disease as Universal Risk Factor

  • Pre-existing chronic liver disease (hepatitis B, hepatitis C, or alcoholic cirrhosis) significantly increases mortality across all acute viral hepatitides 1, 4, 3

Geographic and Genotype Variations

  • HEV genotypes 1 and 2 (Asia, Africa, Mexico) cause epidemic disease with high maternal mortality, while genotypes 3 and 4 (high-income countries) typically cause milder zoonotic infections 1

Critical Pitfall to Avoid

  • Delaying hepatitis A vaccination in patients with chronic hepatitis B, C, or alcoholic liver disease represents a preventable cause of fulminant hepatitis mortality 4, 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Fulminant hepatitis A in patients with chronic liver disease.

Canadian journal of public health = Revue canadienne de sante publique, 2000

Guideline

Hepatitis D Infection Dependence on Hepatitis B

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Critical Management of Fulminant Hepatic Failure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.